DNA repair and cytotoxic drugs: the potential role of RAD51 in clinical outcome of non-small-cell lung cancer patients

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2013

Autores

Augusto Nogueira (Autor) Outra; Joana Assis (Autor) Outra; Raquel Catarino (Autor) Outra; Rui Medeiros (Autor) ICBAS

Revista

Título: Pharmacogenomics

Vol. 14

Páginas: 689-700

ISSN: 1462-2416

Editora: ASHLEY PUBLICATIONS LTD

Indexação

ISI Web of Knowledge - 19 Citações

Scopus - 20 Citações

Classificação Científica

FOS: Ciências médicas e da saúde > Medicina básica

Outras Informações

ID Authenticus: P-005-24M

DOI: 10.2217/pgs.13.48

Abstract (EN): Many of the cytotoxic drugs used in the treatment of non-small-cell lung carcinoma patients can interfere with DNA activity and the definition of an individual DNA repair profile could be a key strategy to achieve better response to chemotherapeutic treatment. Although DNA repair mechanisms are important factors in the prevention of carcinogenesis, these molecular pathways are also involved in therapy response. RAD51 is a crucial element in DNA repair by homologous recombination and has been shown to interfere with the prognosis of patients treated with chemoradiotherapy. There is increasing evidence that genetic polymorphisms in repair enzymes can influence DNA repair capacity and, consequently, affect chemotherapy efficacy. We conducted this review to show the possible influence of the RAD51 genetic variants in damage repair capacity and treatment response in non-small-cell lung carcinoma patients.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 12